Completing the Arc: targeted inhibition of RET in medullary thyroid cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed.

1. Targeted treatments after chemoradiotherapy failure in a patient with relapsed, advanced non‑small cell lung cancer with on‑therapy circulating tumor biomarker monitoring: A case report.Oncology letters · 2023
   Article
2. Medullary Thyroid Carcinoma With Elevated Serum CEA and Normal Serum Calcitonin After Surgery: A Case Report and Literature Review.Frontiers in oncology · 2020
   Article
3. Landscape of gene fusions in epithelial cancers: seq and ye shall find.Genome medicine · 2015
   Review
4. Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine.BMC cancer · 2015
   Article
5. Medical management of metastatic medullary thyroid cancer.Cancer · 2014
   Review
6. RET revisited: expanding the oncogenic portfolio.Nature reviews. Cancer · 2014
   Review
7. The pro-inflammatory cytokines IL-1β and TNFα are neurotrophic for enteric neurons.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2013
   Article
8. Targeted therapies in development for non-small cell lung cancer.Journal of carcinogenesis · 2013
   Review
9. Novel targets in non-small cell lung cancer: ROS1 and RET fusions.The oncologist · 2013
   Review
10. Vandetanib: in medullary thyroid cancer.Drugs · 2012
    Review
11. RET/GFRα signals are dispensable for thymic T cell development in vivo.PloS one · 2012
    Article
12. Emerging role of multikinase inhibitors for refractory thyroid cancer.Biologics : targets & therapy · 2012
    Article

Corrections and comments

• Commented on by
  Progress in molecular targeted therapy for thyroid cancer: vandetanib in medullary thyroid cancer.2012
• Comment on
  Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.2012

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as